Microcapsule slurries can be formed from a phosphate ester and a multivalent ion. The microcapsules can encapsulate a core material misicible with the phosphate ester. The phosphate ester can be lipophilic and insoluble in aqueous solutions.

The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Microcapsule slurries can be formed from a phosphate ester and a multivalent ion. The microcapsules can encapsulate a core material misicible with the phosphate ester. The phosphate ester can be lipophilic and insoluble in aqueous solutions.

Microcapsules can be formed of a phosphate ester and a multivalent ion. The microcapsules can encapsulate a core material having a C log P value of about 0 or greater. The phosphate ester can be lipophilic and insoluble in aqueous solutions.

Rett syndrome (RTT), a childhood neurological disorder that affects primarily females, may be treated by use of a galanthamine analog wherein the hydroxy group of galantamine is replaced of a carbarnate, carbonate or ester group and the methoxy group may be replaced by another alkoxy group of from two to six carbon atoms, a hydroxy group, hydrogen, an alkanoyloxy group or 2 to 10 carbon atoms, a benzoyloxy or substituted benzoyloxy group, a carbonate group of 1 to 10 carbon atoms or a carbamate group such as a mono alkyl or dialkyl or an aryl carbamate wherein the alkyl grottos or aryl groups contain from 1 to 10 carbons; and the N-methyl group may be replaced by hydrogen, alkyl of 1 to 10 carbon atoms benzyl, cyclopropylmethyl group or a substituted or unsubstituted benzoyloxy group. Galantamine mon-alkylcarbarnates are particularly useful.

The invention provides novel antibiotic protocells comprising mesoporous nanoparticles encapsulated within a lipid bi- or multilayer. The nanoparticles have pore sizes and surface chemistries that enable facile adsorption and intracellular presentation of antibiotics which are effective in the treatment of a wide variety of bacterial infections, including F. tularensis, B. pseudomallei and P. aeruginosa-related infections. Related pharmaceutical compositions and methods of treatment are also provided.

A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.